AZTherapies has announced that former Dooner Laboratories and Muro Pharmaceuticals CEO George D. Behrakis has joined the company’s board of directors. Behrakis sold Dooner Laboratories, which manufactured theophylline products for asthma, to Rorer in 1977 and Muro Pharmaceuticals, which marketed a number of OINDPs for the treatment of asthma and allergies, to Degussa’s Asta Medica in 1996.
Behrakis commented, “AZTherapies is increasingly being recognized for its innovative approach to Alzheimer’s and other neurodegenerative diseases. As an investor in the company, I am especially excited to be joining the board at this time and look forward to working with my fellow board members and the company’s executive management team to help realize their mission and make meaningful progress for patients.”
AZTherapies Founder, CEO, and Chairman David R. Elmaleh said, “We are pleased to welcome George to our Board. We believe that his leadership and broad biopharma business acumen will be of great value to us as we advance towards commercialization of our lead program in Alzheimer’s disease and expand our clinical pipeline of candidates targeting neuroinflammation to slow or halt the progression of neurodegenerative diseases.”
Read the AZTherapies press release.
